Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

Phase 2 Completed 136 enrolled Idorsia Pharmaceuticals Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Placebo-controlled study to evaluate the efficacy and safety of oral ACT-539313 in the treatment of adults with moderate to severe binge eating disorder

Timeline

Start: 2021-02-16
Primary completion: 2022-03-21
Completion: 2022-03-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	nivasorexant	Small molecule	100 mg	Oral

Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

Summary

Timeline

Drugs

Indications